The Gulf Journal of Dermatology and Venereology ABSTRACT Background: Etanercept, a tumor necrosis factor antagonist, is an approved biologic agent for treatment of chronic plaque psoriasis in the United States and Europe. Objective: To observe the efficacy and safety profile of etanercept in patients with moderate to severe plaque psoriasis. Methods: In this retrospective study, 56 patients wer...

Plaque psoriasis is a chronic disease requiring long-term therapy. However, real-world treatment patterns and costs are not well characterized. This study examined healthcare among patients newly initiating biologic or apremilast for moderate-to-severe plaque psoriasis. Included had ?1 prescription secukinumab, ixekizumab, adalimumab, ustekinumab, etanercept, between 01/01/2015 08/31/2018, no p...

Biologic agents were introduced during the past decade as a new class of treatments for chronic psoriasis. These agents provide therapeutic alternatives to traditional topical and systemic therapies. Alefacept, the first such biologic agent, was approved by the US FDA in January 2003 for the treatment of chronic plaque psoriasis. This review will discuss data from clinical trials that have prov...

BACKGROUND Limited information exists regarding paediatric psoriasis and its association with body mass index (bMI) in Asia. OBJECTIVES to determine the clinico-epidemiological profile and to compare the bMI of children with and without psoriasis. METHODS A case-control study of 92 children with psoriasis versus 59 with atopic eczema and 56 with non-inflammatory skin conditions. RESULTS P...

BACKGROUND Efalizumab, a T-cell-targeted, recombinant, humanized, monoclonal IgG1 antibody, inhibits key T-cell-mediated steps in the pathogenesis of psoriasis. Efalizumab is approved for the treatment of moderate-to-severe chronic plaque psoriasis in adults in more than 50 countries. OBJECTIVES To evaluate the efficacy and safety of long-term, continuous efalizumab therapy in patients with p...

• Interleukin (IL)-23 and IL-17 play an important role in the development of psoriasis. • Many of the new biologic drugs targeting IL-23 and IL-17 have been shown to be both safe and effective in treating moderate-to-severe plaque psoriasis. Long-term safety data still need to be established. • These drugs are more selective with inhibition of " downstream " targets in the immunopathogenesis of...

BACKGROUND Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are thought to be associated with the pathogenesis and spread of psoriatic disease. This study was designed to investigate the plasma levels of MMP-3, MMP-9 and TIMP-3 in plaque psoriasis patients prior to and following a course of ultraviolet B narrowband treatment with respect to disease advancement. METHODS Pla...

INTRODUCTION AND OBJECTIVES Psoriasis is a chronic inflammatory disease that has been linked to increased cardiovascular risk. The glycoprotein clusterin (apolipoprotein J) is a component of high-density lipoproteins and has a protective role in atherosclerosis. The aim of the present study was to evaluate the plasma levels of clusterin and the proinflammatory cytokine macrophage migration inhi...

OBJECTIVES The balance of service provision for people with psoriasis across community and hospital sectors is inappropriate in many localities. Disease-specific models are being used by policy makers to inform public health decision making and guide their long-term budgets. The aim of the present study was to develop an interactive psoriasis model to compare the 2-year outcomes of topical trea...